Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
PLoS ONE, Volume 8, No. 5, Article e63480, Year 2013
Notification
URL copied to clipboard!
Description
Objectives: To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods: Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 μg or 44 μg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Results: Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as "lack of efficacy" (3.3% vs. 1.7%), "scheduled stop" (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 mg vs. 44 mg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Conclusions: Treatment discontinuations were more common in interferon "-1a 22 μg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from "real-world" database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry. © 2013 Kalincik et al.
Authors & Co-Authors
Kalincik, Tomas
Australia, Melbourne
University of Melbourne
Spelman, Tim D.
Australia, Melbourne
Royal Melbourne Hospital
Trojano, Maria
Italy, Bari
Università Degli Studi Di Bari Aldo Moro
Duquette, Pierre Pascal
Canada, Montreal
Hôpital Notre-dame
Izquierdo, Guillermo Ayuso
Spain, Sevilla
Hospital Universitario Virgen Macarena
Grammond, Pierre
Canada, Levis
Hotel-dieu de Levis Hospital
Lugaresi, Alessandra
Italy, Chieti
University of G. D'annunzio Chieti and Pescara
Hupperts, Raymond M.M.
Netherlands, Sittard
Maasland Hospital Sittard
Cristiano, Edgardo
Argentina, Buenos Aires
Instituto Universitario Del Hospital Italiano de Buenos Aires
van Pesch, Vincent
Belgium, Brussels
Cliniques Universitaires Saint-luc
Grand'Maison, François
Canada, Greenfield Park
Hôpital Charles-le Moyne
Spitaleri, Daniele Litterio A.
Italy, Avellino
Aorn San Giuseppe Moscati
Rio, Maria Edite
Portugal, Porto
Sao Joao Hospital
Flechter, Schlomo
Israel, Beer Yacov
Shamir Medical Center
Oreja-Guevara, Celia
Spain, Madrid
Hospital Clínico San Carlos
Giuliani, Giorgio
Italy, Macerata
Ospedale Di Macerata
Savino, Aldo
Argentina, Buenos Aires
Consultorio Privado
Amato, Maria Pia
Italy, Florence
Università Degli Studi Di Firenze
Petersen, Thor K.
Denmark, Aarhus
Aarhus Universitetshospital
Fernández-Bolaños, Ricardo
Spain, Sevilla
Hospital Universitario de Valme
Bergamaschi, Roberto
Italy, Pavia
Irccs Fondazione Mondino
Iuliano, Gerardo
Italy, Salerno
Ospedali Riuniti Di Salerno
Boz, Cavit
Turkey, Trabzon
Karadeniz Technical University
Lechner-Scott, Jeannette S.
Australia, Newcastle
John Hunter Hospital
Deri, Norma Haydee
Argentina, Buenos Aires
Hospital General de Agudos Juan Fernandez
Gray, Orla M.
United Kingdom, Portadown
Craigavon Area Hospital
Verheul, Freek A.M.
Unknown Affiliation
Fiol, Marcela Paula
Argentina, Buenos Aires
Fundacion Para la Lucha Contra Las Enfermedades Neurologicas de la Infancia
Barnett, Michael H.
Australia, Sydney
The University of Sydney
van Munster, Erik Th L.
Netherlands, 's-hertogenbosch
Jeroen Bosch Hospital
Santiago, Vetere
Argentina, La Plata
Higa Gral
Moore, Fraser G.A.
Canada, Montreal
Sir Mortimer B. Davis Jewish General Hospital
Slee, Mark
Australia, Adelaide
Flinders University
Saladino, María Laura
Argentina, Buenos Aires
Ineba
Alroughani, Raed A.
Kuwait, Safat
Al-amiri Hospital
Shaw, Cameron P.
Australia, Geelong
Geelong Hospital
Kása, Krisztián
Hungary, Budapest
Jahn Ferenc Dél-pesti Kórház, Budapest
Petkovska-Boskova, Tatjana
North Macedonia, Skopje
Clinic of Neurology Clinical Center
den Braber-Moerland, Leontien
Netherlands, Roosendaal
Francicus Ziekenhuis
Chapman, Joab C.
Israel, Tel Hashomer Tel Aviv
Chaim Sheba Medical Center Israel
Skromne, Eli
Mexico, Mexico
Hospital Angeles México
Herbert, Joseph
United States, New York
Nyu Langone Orthopedic Hospital
Poehlau, Dieter
Germany, Asbach
Kamillus-klinik
Needham, Merrilee
Australia, Sydney
Royal North Shore Hospital
Bacile, Elizabeth Alejandra
Argentina, Cordoba
Instituto Neurociencias Cordoba
Arruda, Walter Oleschko
Brazil, Curitiba
Hospital Ecoville
Paine, Mark A.
Australia, Fitzroy
St. Vincent's Hospital Melbourne
Singhal, Bhim Sen
India, Mumbai
Bombay Hospital and Medical Research Centre
Vucic, Steve
Australia, Sydney
Westmead Hospital
Cabrera-Gömez, José Antonio
Cuba, Havana
Centro Internacional de Restauración Neurológica
Butzkueven, Helmut
Australia, Melbourne
University of Melbourne
Australia, Clayton
Monash University
Statistics
Citations: 128
Authors: 51
Affiliations: 50
Identifiers
Doi:
10.1371/journal.pone.0063480
e-ISSN:
19326203
Research Areas
Disability
Study Design
Case-Control Study